Orexigen Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Orexigen Therapeutics sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Orexigen Therapeutics: 17 sponsored US clinical trials, none currently recruiting.
Orexigen Therapeutics sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 7 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 3 trials.
Top-decile sponsor footprint
Orexigen Therapeutics ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants
NCT02735603
Naltrexone/Bupropion Cardiovascular Outcomes Study
NCT02638129
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
NCT02259179
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
NCT01764386
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
NCT01601704
A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
NCT00711477
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
NCT00758966
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
NCT00709371
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
NCT00624858
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
NCT00567255
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
NCT00532779
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
NCT00563563
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
NCT00474630
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
NCT00456521
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
NCT00339014
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
NCT00364871
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Therapeutic Areas
How the Orexigen Therapeutics archive is shaped
17 indexed studies, none listed as recruiting (0% open); 13 completed (76%).
Phase mix: 7 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Obesity (3 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Orexigen Therapeutics: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Orexigen Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Orexigen Therapeutics page
17 registered trials is a research-attention snapshot, not an endorsement of Orexigen Therapeutics or any single study.
- None of Orexigen Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Obesity is the condition Orexigen Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Orexigen Therapeutics pipeline card: 17 registered trials from official public datasets.Report a data error.